IBRX

ImmunityBio (IBRX)

ImmunityBio Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:IBRX

1 2 3 4 5 6 7 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/05/17	22 : 00	Business Wire	Connecting the Dots of ANKTIVA’s Triangle Offense: A Deep Dive with Dr. Patrick Soon-Shiong and Dr. Ashish Kamat in a Three-Part UroToday Podcast	NASDAQ:IBRX	ImmunityBio Inc
2024/05/10	06 : 00	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:IBRX	ImmunityBio Inc
2024/05/07	21 : 00	Business Wire	ImmunityBio Completes GMP Drug Substance Manufacturing Sufficient for 170,000 Doses of ANKTIVA®	NASDAQ:IBRX	ImmunityBio Inc
2024/05/03	05 : 04	Business Wire	ImmunityBio, Serum Institute of India Agree on an Exclusive Arrangement for Global Supply of Bacillus Calmette-Guerin (BCG) Across All Cancer Types	NASDAQ:IBRX	ImmunityBio Inc
2024/04/30	21 : 00	Business Wire	ImmunityBio Executive Chairman Dr. Patrick Soon-Shiong to Discuss ANKTIVA® Approval in Fireside Chat at the Annual Conference of the American Urological Association	NASDAQ:IBRX	ImmunityBio Inc
2024/04/25	13 : 03	Business Wire	ImmunityBio Announces Positive Overall Survival Results of Anktiva Combined With Checkpoint Inhibitors in Non-Small Cell Lung Cancer; Meeting Scheduled with FDA to Discuss Registration Path for ANKTIVA in Lung Cancer	NASDAQ:IBRX	ImmunityBio Inc
2024/04/23	10 : 56	Business Wire	ImmunityBio Announces FDA Approval of ANKTIVA®, First-in-Class IL-15 Receptor Agonist for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer	NASDAQ:IBRX	ImmunityBio Inc
2024/03/06	23 : 00	Business Wire	NIAID-Sponsored Study Shows N-803 Combined with Neutralizing Antibodies Could Lead to Sustained HIV Viral Control After Discontinuation of Antiretroviral Therapy	NASDAQ:IBRX	ImmunityBio Inc
2024/03/05	23 : 00	Business Wire	N-803 Combined with Natural Killer Cells Showed Potential to Reduce HIV Viral Load in HIV Positive Subjects; Part of HIV Cure Study	NASDAQ:IBRX	ImmunityBio Inc
2024/02/27	06 : 43	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:IBRX	ImmunityBio Inc
2024/02/27	06 : 40	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:IBRX	ImmunityBio Inc
2024/02/27	06 : 38	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:IBRX	ImmunityBio Inc
2024/02/24	11 : 28	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:IBRX	ImmunityBio Inc
2024/02/21	23 : 00	Business Wire	ImmunityBio Announces Full Accrual of First Two Phases of Cancer Vaccine Trial in Participants with Lynch Syndrome and Initiation of Randomized Controlled Phase of the Trial	NASDAQ:IBRX	ImmunityBio Inc
2024/02/07	11 : 14	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:IBRX	ImmunityBio Inc
2024/02/05	23 : 00	Business Wire	ImmunityBio Quality-of-Life Study in BCG-Unresponsive Bladder Cancer Trial Indicates Improved Physical Function in the 71% Complete Responders Suggesting a Favorable Risk-Benefit Ratio for N-803 Plus BCG	NASDAQ:IBRX	ImmunityBio Inc
2024/02/03	09 : 38	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:IBRX	ImmunityBio Inc
2024/02/03	09 : 33	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:IBRX	ImmunityBio Inc
2024/01/04	11 : 59	Edgar (US Regulatory)	Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]	NASDAQ:IBRX	ImmunityBio Inc
2024/01/04	11 : 41	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:IBRX	ImmunityBio Inc
2024/01/04	11 : 40	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:IBRX	ImmunityBio Inc
2024/01/02	20 : 08	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:IBRX	ImmunityBio Inc
2024/01/02	20 : 00	Business Wire	ImmunityBio Announces $320 Million Investment by Oberland Capital, with $210 Million Funded at Closing, Bringing Total Financing in 2023 to $850 Million	NASDAQ:IBRX	ImmunityBio Inc
2023/11/16	23 : 00	Business Wire	ImmunityBio to Participate in 35th Annual Piper Sandler Healthcare Conference	NASDAQ:IBRX	ImmunityBio Inc
2023/11/09	11 : 28	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:IBRX	ImmunityBio Inc
2023/11/07	23 : 00	Business Wire	First Data for ImmunityBio’s Memory Cytokine-Enriched NK Cells in Small Cell Lung Cancer at SITC Meeting Show Promising Anti-tumor Activity	NASDAQ:IBRX	ImmunityBio Inc
2023/10/27	01 : 03	Dow Jones News	ImmunityBio Shares Rally as FDA Accepts N-803 Resubmission	NASDAQ:IBRX	ImmunityBio Inc
2023/10/26	22 : 00	Business Wire	FDA Accepts ImmunityBio’s BLA Resubmission as Complete and Sets New PDUFA Date	NASDAQ:IBRX	ImmunityBio Inc
2023/10/24	00 : 00	Dow Jones News	ImmunityBio Shares 11% Higher on License Application Resubmission for N-803	NASDAQ:IBRX	ImmunityBio Inc
2023/10/23	22 : 00	Business Wire	ImmunityBio Announces Biological License Application Resubmission for N-803 in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer Carcinoma-In-Situ	NASDAQ:IBRX	ImmunityBio Inc